TG Therapeutics Inc (TGTX)
🔔 Watch stock
symbol.quality_heading
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
The value signal is real — a profitable, growing biotech with a clean balance sheet — but it deceives about the earnings quality: three quarters of the 2025 record profit is a one-time tax bonus, and almost all the revenue hangs on a single drug against Roche and Novartis. The case is a bet on the further commercialization of BRIUMVI and on the pipeline moving up, at a valuation that already prices in a lot, and with a freshly burdened balance sheet. If the operating profit grows into the valuation, the bet can pay off; if growth stalls, a high expectation meets a one-product business. The decision is yours.
symbol.quality_note
TG Therapeutics sells a single drug — BRIUMVI, an infusion against relapsing multiple sclerosis — and is thereby the rare profitable biotech in our value scanner after Joel Greenblatt's Magic Formula. Net product revenue rose from $92 million (2023) to $606.9 million (2025), and the bottom line showed a record profit of $447.2 million. We read the annual report (10-K) for 2025 and the quarterly report (10-Q) as of March 31, 2026: three quarters of that profit is a one-time tax bonus, nearly all the revenue hangs on this one drug, and the rivals are named Roche and Novartis. A sober reckoning behind a genuine success story — and no, this is not investment advice.
Read the analysis
Stock Watch
This analysis is as of July 15, 2026. Stock Watch will tell you what's changed at TGTX since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 30 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 52.00 $ — 78% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralGeprüft am 14.07.2026 gegen den Geschäftsbericht (10-K) 2025 (eingereicht 27.02.2026), den Geschäftsbericht 2024 (03.03.2025) sowie die vier jüngsten Quartalsberichte (10-Q) bis zum 31.03.2026. In den ausgewerteten SEC-Filings von TG Therapeutics findet sich kein wesentlicher KI-Bezug: Das Geschäft dreht sich vollständig um B-Zell-Erkrankungen und den anti-CD20-Antikörper BRIUMVI (ublituximab-xiiy) gegen Multiple Sklerose. „Artificial intelligence“ taucht ausschließlich als Risk-Factor-Thema auf — und dort nur in einer spekulativen „may adopt, use or incorporate“-Formulierung (das Unternehmen „könnte“ künftig KI in seine IT-Systeme aufnehmen) plus generischer Regulierungs- und Cybersecurity-Boilerplate (EU AI Act, „AI-washing“). Es gibt keine KI-Umsatzquelle, keinen belegten operativen KI-Einsatz im Geschäftsmodell und kein konkretes KI-Geschäftsrisiko fürs eigene Modell. Nach dem Kriterienkatalog bleibt es damit bei „Neutral“ (dokumentierter Negativ-Befund).
View the full file — quotes, sources, reviewed filings
„We, directly or through our third-party service providers, may adopt, use or incorporate AI technology and capabilities into information technology systems or software to help us operate our business more efficiently than existing industry tools."
Wir könnten — direkt oder über unsere externen Dienstleister — KI-Technologie und -Fähigkeiten in IT-Systeme oder Software aufnehmen, nutzen oder einbinden, um unser Geschäft effizienter zu betreiben als mit bestehenden Branchenwerkzeugen.
„TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases."
TG Therapeutics ist ein voll integriertes Biotechnologie-Unternehmen in der kommerziellen Phase, das sich auf die Akquisition, Entwicklung und Vermarktung neuartiger Behandlungen für B-Zell-Erkrankungen konzentriert.
Filings Reviewed: 10-Q 2026-05-06 · 10-Q 2025-11-05 · 10-Q 2025-08-08 · 10-Q 2025-05-09 · 10-K 2026-02-27 · 10-K 2025-03-03
Rated on July 14, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 31.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.57 | 1.30 – 1.82 | 943 | -43.2% | 6 |
| 12/31/2027 | 3.28 | 2.32 – 4.27 | 1,292 | 108.7% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.41 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.15 | – | 108 | 146.00 | 21.60 | -26 | -26 |
| 2025: Q1 | 0.03 | – | 121 | 90.40 | 4.20 | -29 | -29 |
| 2025: Q2 | 0.17 | 301.90 | 141 | 92.10 | 20.00 | 7 | 7 |
| 2025: Q3 | 2.43 | 9,956.80 | 162 | 92.80 | 241.70 | -23 | -23 |
| 2025: Q4 | 0.14 | -0.70 | 193 | 78.00 | 12.00 | 20 | 20 |
| 2026: Q1 | 0.12 | 297.50 | 205 | 69.60 | 9.70 | -18 | -18 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -79 | -78 | -1.60 | -62 | 36 | 55 |
| 2017 | 0 | -119 | -118 | -1.91 | -94 | 67 | 97 |
| 2018 | 0 | -174 | -173 | -2.30 | -129 | 24 | 84 |
| 2019 | 0 | -169 | -173 | -1.96 | -133 | 39 | 163 |
| 2020 | 0 | -274 | -279 | -2.42 | -215 | 519 | 626 |
| 2021 | 7 | -345 | -348 | -2.63 | -296 | 237 | 380 |
| 2022 | 3 | -218 | -224 | -1.65 | -176 | 59 | 194 |
| 2023 | 234 | 21 | 13 | 0.09 | -31 | 161 | 330 |
| 2024 | 329 | 42 | 23 | 0.15 | -41 | 222 | 578 |
| 2025 | 616 | 123 | 447 | 2.77 | -25 | 648 | 1,063 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
BRIUMVI is growing impressively: net product revenue from $92.0 million (2023) to $606.9 million (2025), Q1 2026 alone $201.3 million (plus about 68 percent). The rare case of a profitable biotech with a clear product advantage (short infusion) in a growing MS segment.
The record 2025 net income of $447.2 million consists of only $107.4 million from the business; $339.8 million is a one-time, non-cash tax bonus from the release of the valuation allowance on deferred taxes. The price-to-earnings ratio therefore looks cheaper than the operating result justifies.
Positive equity ($583.1 million, 31.03.2026), Altman-Z 6.15, about $572.8 million in cash — no distress. At the same time an accumulated deficit of about $1.1 billion, and in March 2026 the loan was increased from $250 million to $750 million (secured by all assets) with a simultaneous share buyback.
About 98 percent of revenue hangs on a single drug — "our only marketed product". In the MS market BRIUMVI competes with ocrelizumab (Roche, Ocrevus) and ofatumumab (Novartis, Kesimpta), both from significantly larger corporations; on the horizon possible new BTK inhibitors.
Market value about $8.3 billion, P/S about 12, P/B about 15 — ambitious for a one-product business; Weinstein Stage 2, institutional accumulation, about 79 percent price gain over six months and a buy-leaning analyst consensus. Plenty of success is priced in (data as of July 8, 2026).
TG Therapeutics is the rare profitable biotech in the value scanner: BRIUMVI, an anti-CD20 agent against multiple sclerosis, has driven revenue from $92 million to $606.9 million and pushed the company into the profit zone. But the 2025 record profit is three quarters a one-time tax bonus, about 98 percent of the business hangs on this one product, and the rivals are named Roche and Novartis. Positive equity and full coffers stand against a loan freshly increased to $750 million. Not investment advice.
- Membership in the value scanner "Joel Greenblatt: Magic Formula" (not a warning scanner) was confirmed locally and live on July 14, 2026; TGTX shows up in 27 value, quality and momentum scanners, in no warning scanner.
- All earnings and balance-sheet figures come from the verified annual report 10-K for 2025 (filed 27.02.2026) and the quarterly report 10-Q as of 31.03.2026; the 2025 net income contains a one-time income tax benefit of $339.8 million from the release of the valuation allowance on deferred taxes.
- Price and valuation figures dated to July 8, 2026 (about $53.60, about 155 million shares); analyses are evergreen, daily prices are not a buy argument.
About the Company
TG Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Akquisition, Entwicklung und Kommerzialisierung neuartiger Behandlungen für B-Zell-vermittelte Erkrankungen in den USA und international konzentriert.
| Employees | 399 |
|---|---|
| Headquarters | Morrisville, NC |
| Address | 3020 Carrington Mill Blvd., 27560 Morrisville, United States |
| Phone | 212 554 4484 |
| Website | tgtherapeutics.com |
| IPO Date | 14. Dec 1995 |
| ISIN | US88322Q1085 |
| Stock Split | 100:5625 on 04/30/2012 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Michael S. Weiss Esq., J.D. | Chairman, CEO & President | 1966 |
| Sean A. Power CPA | CFO, Corporate Secretary & Treasurer | 1982 |
| Jenna Bosco | Senior Vice President of Corporate Communications | – |
| Adam Waldman | Chief Commercialization Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.